Among these we identified four genes, perlecan/HSPG2, LAMB3, LOXL2, and SRPX, that were significantly associated with clinical outcomes in patients with PC: perlecan/HSPG2 and LOXL2 gene expression correlated with worse BRFS, whereas SRPX and LAMB3 correlated with better BRFS. Here, HSPG2 is linked to pachyonychia congenita.